Adan Medical Innovation Announces Launch of Clinical Trial for anAPPhylaxis-Its Smart Case and Mobile Phone App for Epinephrine Autoinjectors
(Thomson Reuters ONE) -
BARCELONA, Spain, April 25, 2016 (GLOBE NEWSWIRE) -- Adan Medical Innovation,
SL. (Adan MI), a privately held biotech firm developing advanced tools and
medical devices that assist in the maintenance, portability and storage of
pharmaceutical drugs, today announced the launch of the company's first clinical
trial for its leading medical device,anAPPhylaxis (pronounced: an-APP-fil-laks-
es).
A video accompanying this release is available
at http://www.globenewswire.com/NewsRoom/AttachmentNg/654605a0-b5e9-4f0e-8139-
baf1ba3453c2
anAPPhylaxis is a combination of a smart case and corresponding mobile phone
application for use in managing an epinephrine autoinjector, the primary
treatment for anaphylaxis, a serious allergic reaction. anAPPhylaxis provides
readings regarding the storage conditions, effectiveness and physical proximity
of the epinephrine autoinjector through a wireless Bluetooth® connection with a
smart phone, and issues alerts to warn the patient if there is a separation
between the patient and their device, or if the environment the case is stored
in is unacceptable.
If anaphylaxis does occur, the anAPPhylaxis mobile app is designed to
automatically issue alerts to a pre-determined list of contacts and/or emergency
services, providing each with the location where the smart case was opened. The
app will then proceed to play a video demonstrating the proper method of using
the epinephrine autoinjector for the person, caregiver, or whomever may be
assisting the person experiencing anaphylaxis.
"There isn't anything in the market like what we have created-an innovative and
effortless device that pairs biotechnology and mobile health," said Adan MI CEO
Xavier Guillem. "This convergence of these two fields is groundbreaking, and we
are only just beginning to implement the potential of this technology."
The clinical trial is being conducted at the largest hospital complex in Spain,
the Hospital Universitari Vall d'Hebron in Barcelona with the primary endpoint
of evaluating the satisfaction with the use of the anAPPhylaxis medical device
by patients. Secondary endpoints include evaluating quality of life, adherence
to medical requirements and measurement of perceived anxiety regarding use in
the event of anaphylaxis.
Adan MI Co-Founders, Drs. Anna Sala and Adrian Curran, developed the idea for a
medical device from the daily testimonials, concerns and opinions they heard
from their patients regarding the challenges of carrying, maintaining and
storing their epinephrine autoinjectors on a daily basis.
About Adan Medical Innovation (Adan MI)
Adan Medical Innovation (Adan MI) is a privately held biotechnology firm
committed to making a difference in the lives of individuals, families and
caregivers who manage an epinephrine autoinjector for use in the event of
anaphylaxis, a potentially serious and fatal allergic reaction. Adan MI's
leading medical device is anAPPhylaxis, a combination of a smart epinephrine
autoinjector case and a corresponding mobile phone application that provides
readings regarding the storage conditions and physical proximity of an
individual's epinephrine autoinjector through a wireless Bluetooth® connection
on a smart phone. For more information, visit www.adanmi.com.
Media Contacts:
Juliette Bogus
B Squared Communications
410.980.5687
Juliette(at)bsquaredllc.net
Chris Bogus
B Squared Communications
443.682.1237
Chris(at)bsquaredllc.net
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Adan Medical Innovation, S.L. via GlobeNewswire
[HUG#2006529]
Datum: 25.04.2016 - 16:25 Uhr
Sprache: Deutsch
News-ID 466224
Anzahl Zeichen: 4407
contact information:
Town:
Barcelona
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 219 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Adan Medical Innovation Announces Launch of Clinical Trial for anAPPhylaxis-Its Smart Case and Mobile Phone App for Epinephrine Autoinjectors"
steht unter der journalistisch-redaktionellen Verantwortung von
Adan Medical Innovation, S.L. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
